Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and ...

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.2% in the afternoon session after the stock extended ...

The deal allows Eli Lilly and Company (NYSE:LLY) to have exclusive rights to develop and commercialize drug candidates ...

Eli Lilly (LLY) has signed a $1.3 billion deal with privately held biotechnology firm Superluminal Medicines that will see ...

Superluminal Medicines, a healthcare company integrating AI/ML, announced partnership with Eli Lilly (NYSE:LLY) to advance ...

Eli Lilly has a market value of more than $420 billion, and sells blockbuster treatments for diabetes and cancer. It's already begun to invest in a host of projects focused on AI.

Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy according to analysts. On August 14, Eli Lilly and ...

AI is thus poised to radically transform the pharmaceutical industry. Two of the leading players in this field are Eli Lilly (LLY 0.84%) and GSK (GSK -0.68%), both of which have invested heavily ...

Continuing my search for examples of Practical AI, I found a great one in a recent discussion with Vipin Gopal, chief data and analytics officer at Eli Lilly, the $28.31 billion (2021 revenues ...